We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are ...

Johnson & Johnson (J&J) has announced that its Tremfya (guselkumab) has been recommended by the European Medicines Agency’s ...

New antibiotic has been approved for uncomplicated UTIs; Cabometyx approved for advanced neuroendocrine tumors; new rosacea treatment option; Tremfya ...

The FDA has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active Crohn disease.

Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn’s disease 1,2,3 Beerse, Belgium (28 March 2025) – Johnson & Johnson today announced that the ...

Johnson & Johnson (NYSE:JNJ) experienced an 11% price increase over the last quarter. This movement coincided with several ...

In December 2024, the American Gastroenterological Association (AGA) published an updated clinical guideline for the ...

Fears of a looming recession seem to be rising, partly fueled by President Donald Trump's macroeconomic policies. Medtronic (NYSE: MDT) and Johnson & Johnson (NYSE: JNJ) are excellent examples along ...

Top health care investment bankers say that large deals involving pharmaceutical and biotech companies are stalling as executives grapple with ...